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PrognosticThe overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are
b15%. Hence, melanoma detection in earlier stages (stages I–III) maximises the chances of patient survival. We
measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III;
n = 76 and IV; n = 10) and serum samples (collected from controls with no melanoma, n = 130; and patients
with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and
Germany. In melanoma tissues, members of the ‘MELmiR-17’ panel were found to be predictors of stage,
recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7)
detected the presence of melanoma (relative to controls) with high sensitivity (93%) and speciﬁcity (≥82%)
when ≥4 miRNAs were expressed. Moreover, the ‘MELmiR-7’ panel characterised overall survival of melanoma
patients better than both serum LDH and S100B (delta log likelihood = 11, p b 0.001). This panel was found to
be superior to currently used serological markers for melanoma progression, recurrence, and survival; and
would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease
(stages IIIa–c/IV M1a–b) to detect relapse following surgical or adjuvant treatment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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markers have been used formany years however it is clear from the survival rates (5-year survival of Stage IV patients is b15%)
s thus highlighting that the current methods of progression detection are inadequate. We have identiﬁed a seven-miRNA panel
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Table 1
Descriptive statistics for tissue cohorts.
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Melanomas are among themost commonly occurring cancers. Crude
incidence rates in Australia (AIHW, 2014) and the USA (SEER, 2014)
were approximately 50 cases (in 2010) and 20 cases (in 2011) per
100,000 respectively. With the number of new cases rising each year,
melanoma is currently is listed as the 4th and 6thmost common cancer
in Australia and the USA respectively (AIHW, 2014; SEER, 2014).
Current clinical staging criteria classify melanoma progression from
a pre-invasive lesion, conﬁned to the epidermis (stage 0), a series
of early stages of local invasion (I and II), a stage involving regional
lymph nodes (stage III) and ﬁnally metastasis to distant sites (stage
IV). The overall 5-year survival for melanoma is 91%, which is largely
due to curative surgery for early stage disease. However, cure rates
are b15% (Balch et al., 2009) if distant metastasis occurs (stage IV;
AJCC 7th edition). We now have evidence that current therapeutic
options for late stage disease aremore effective if the disease is treat-
ed with a lower disease burden (Sosman et al., 2012; Hodi et al.,
2010). Hence, melanoma must be treated in earlier stages to maxi-
mise the chances of patient survival. Therefore, the ability to identify
signs of melanoma progression sooner would be a valuable clinical
tool.
Melanoma progression biomarkers have been studied intensively
with varying levels of success. Serum lactate dehydrogenase (LDH)
levels have been integrated into current staging regimens (Balch
et al., 2009) and elevation of LDH levels increases in speciﬁcity as dis-
ease progresses (stages II (83%), III (87%), and IV (92%)). However
the sensitivity of this marker is reduced during progression (stages
II (95%), III (57%), and IV (79%)) (Brochez and Naeyaert, 2000;
Finck et al., 1983; Karakousis et al., 1996; Sirott et al., 1993; Weide
et al., 2012; Deichmann et al., 1999). S100B, a calcium binding pro-
tein, is raised in serum of stages III and IV melanoma patients (Guo
et al., 1995; Smit et al., 2005). However, the proportion of patients
with elevated S100B levels varies by stage: 0–9% in stages I/II, 5–
98% in stage III, and 40–100% in stage IV (reviewed in Kruijff
et al., 2009). As such, serum S100B is not routinely used in the
clinic (Leiter et al., 2014), highlighting the fact that the current
serological methods of progression detection, whilst relatively
speciﬁc, are inadequate due to variability in sensitivity across all
stages of disease. To date, there are no biomarkers that are sensi-
tive or speciﬁc enough to be beneﬁcial for early detection of
melanoma (all stages). A blood test (‘circulating’ biomarkers)
that detected melanoma with regional spread, prior to clinically
evident distant metastasis, could improve treatment and out-
comes for melanoma patients.
For a circulating biomarker to be effective, not only must it be
sufﬁciently sensitive and speciﬁc, but it must also be highly stable and
resistant to degradation. In recent years, circulating microRNAs
(miRNAs) have been studied for their utility as biomarkers in a
wide range of malignancies and disorders (Allegra et al., 2012;
De Guire et al., 2013). miRNAs are small (20–22 nt) non-coding
RNAs which function to regulate gene expression in the cell. Re-
cently, tumour cells have been shown to release miRNAs into the
circulation (Mitchell et al., 2008), contained primarily in micro-
vesicles or exosomes (extracellular vesicles), or bound to AGO2 — a
part of the miRNA-mediated silencing complex (Allegra et al., 2012;
De Guire et al., 2013). Due to the ‘encapsulation’ of these miRNAs in
serum or plasma they are highly resistant to degradation by RNases
(highly concentrated in the blood), thus their potential usefulness as a
‘biomarker’ is relatively high. To date, circulating melanoma-related
miRNAs have been rarely studied (Fleming et al., 2015; Friedman
et al., 2012).
Hereinwe report amulti-centre study that identiﬁes a panel of ‘mel-
anoma-related’miRNAs that offer superior sensitivity to currently used
serological markers for melanoma progression, recurrence, and
survival.2. Materials and Methods
2.1. Patient Specimen Details
Formalin-ﬁxed parafﬁn-embedded (FFPE) melanoma tissues and
serum (melanoma and control patients) were obtained from prospec-
tively collected biobanks in Australia and Germany.2.2. Tissue Validation Cohort
FFPE melanoma tissues, collected at diagnosis of stage III (PAH-
tissue)were obtained via a database of prospective stage IIIA–C cutaneous
melanoma cases, presenting to the Princess Alexandra Hospital (PAH)
Melanoma Unit and afﬁliated private hospitals, which has been main-
tained since 1997. Permission to collect and use informationwas approved
by the hospital ethics committee (HREC Reference number: HREC/11/
QPAH/650; SSA reference number: SSA/11/QPAH/694). Inclusion criteria
were the same as those previously presented (Tembe et al., 2015). An addi-
tional collection (collected at diagnosis) of stages III and IV melanoma tis-
sues (MIA-tissue) were obtained via a database of prospectively recruited
melanoma cases, presenting to the Melanoma Institute Australia (MIA)
and afﬁliated private hospitals, which has been maintained since 1967. In-
formedwritten consentwas obtained for each patient under approved pro-
tocols (Protocol No. X10-0305 &HREC/10/RPAH/539 and Protocol No. X10-
0300 HREC/10/RPAH/530) governed by the Human Research Ethics
Committee of the Royal Prince AlfredHospital (SydneyNSW, Australia). In-
clusion criteria were the same as those previously presented (Tembe et al.,
2015). See Table 1 for participant descriptive statistics. Supplementary
Table 2 shows the mean, median, and range of follow-up times.
Table 2
Descriptive statistics for serum cohorts.
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Sera from ‘healthy co7ntrols’ were ascertained from a cohort of
participants collected as part of the Australian Cancer Study (ACS)
(QIMR Berghofer HREC approved project no. P399). As part of the
ACS, potential controls were randomly selected from the Australian
Electoral Roll (enrolment is compulsory). Controls were prospec-
tively sampled from within strata of age (in 5 year age-groups) and
state of residence. Of the 3258 potentially eligible control partici-
pants, 41 could not be contacted and 175 were excluded because
they were deceased (16), too ill (61), or unable to read or write in
English (98). Of 3042 controls meeting the inclusion criteria, 1680
(55%) gave their consent to take part. Completed questionnaires
were returned by 1580 controls (48% of all potentially eligible con-
trols selected from the roll). See Table 2 for participant descriptive
statistics.
Sera from ‘high naevus count’ and ‘history of melanoma, disease-
free’ participants were prospectively collected from cohorts who were
enrolled in the study: ‘Pigmentation genotypes and phenotypic correla-
tions with dermoscopic naevus types and distribution’. These samples
were included as ‘controls’ to determine the level of expressionmeasur-
able in sera derived from patients with a high melanocyte burden. All
study participants were enrolled in the following human ethics
approved projects: QIMR HREC/P1237, The Metro South Health District
HREC/09/QPAH/162, and UQ HREC approval number is 2009001590.
Participants with a history of melanoma (clinically free of disease at
time of blood draw) were recruited through the Melanoma Unit and
Dermatology Department of the Princess Alexandra Hospital, Brisbane,
Queensland, Australia, betweenMay 2012 and November 2012. Control
participants, with no personal history of melanoma, were recruited
from the Brisbane Twin Naevus Study between August 2012 andNovember 2012. All participants had 16-panel full-body images and
dermoscopic images of signiﬁcant naevi recorded. Signiﬁcant naevi
were deﬁned as naevi greater than or equal to 5mmon all body sites ex-
cept the scalp, buttocks, mucosal surfaces and genitals, and greater than
or equal to 2mmon the back of bothmales and females and on the legs
of females. All signiﬁcant naevi were classiﬁed by the predominant
dermoscopic pattern (reticular, globular, or non-speciﬁc), colour, and
proﬁle (ﬂat, raised, domed or papillomatous). See Table 2 for participant
descriptive statistics.
The description of ‘controls’ used in the analyses refers to a
combined cohort of ‘healthy controls’, ‘high naevus count’, and ‘history
of melanoma, disease-free’ participants.
2.4. Serum Validation Cohorts: Melanoma Patient Sera
Sera from stages I–IV melanoma patients (at time of blood draw
and staged according to the current AJCC staging manual 3 (Balch
et al., 2009)) had blood drawn and serum stored as part of a large
prospectively collected cohorts from the university department of
dermatology in Tubingen, Germany (‘Tubingen’ cohort) andMelano-
ma Institute of Australia, Sydney (‘MIA’ cohort). Usage of the ‘Tubingen’
bio-bank with corresponding patient data was approved by the Ethics
Committee, University of Tübingen (approvals 657/2012BO2). Serially-
collected stage IV patients (‘MIA’ cohort only) had blood drawn at time
of diagnosis or at lower disease burden and then at higher disease bur-
den (determined by routine diagnostic tests). All samples from the
‘MIA’ cohort had informed written consent obtained from each patient
under approved protocols (Protocol No. X10-0305 &HREC/10/RPAH/
539 and Protocol No. X10-0300 HREC/10/RPAH/530) governed by the
Human Research Ethics Committee of the Royal Prince Alfred Hospital
(SydneyNSW,Australia). See Table 2 for participant descriptive statistics.
Fig. 1. Study summary.
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times.
All serum samples were collected in 10-mL BD serum tubes then
centrifuged for 10 min at 1500 ×g. The supernatant serum was then
aliquoted into 1.5-mL cryovials and stored at −80 °C until further
use.
2.5. Total RNA Extraction From Validation Cohorts
A sterile disposable biopsy punch (Kai Medical, Japan) was used to
retrieve tumour content from blocks that had been scored and marked
for content via H&E histological staining. The extraction of total RNA
from FFPE tissue and serum was performed respectively using
miRNeasy FFPE Kits (Qiagen) as per manufacturer's instructions or as
previously described (Tembe et al., 2015).
2.6. Selection Criteria for ‘Melanoma-related’ miRNAs
In our previously published miRNA microarray dataset (Stark et al.,
2015) we found a total of 233/1898 miRNAs (‘Discovery’ set) (Fig. 1)
thatwere differentially expressed (DE; correctedp ≤0.05 and ≥2-fold) be-
tween the melanoma cell lines (n = 55) and the ‘other’ solid cancers
(n = 34). We applied ﬁltering criteria to the 233 DE miRNAs to identifywhich miRNAs would be suitable to measure in patient derived serum.
The following strict criteria were used to ﬁlter the ‘Discovery’ set:
≥15-fold higher expression in cutaneous melanoma vs. ‘other’ solid
malignancies (n = 14/14), or ≥2-fold higher expression in cutaneous
melanoma vs ‘other’ solid malignancies with no detectable expression
in melanocytes or melanoblasts (n = 3/6). In addition, miR-16, which
is known to be highly expressed in blood, was assessed for its suitability
as an endogenous control. The 18 miRNA panel (MELmiR-18) compris-
ing: miR-211-5p, miR-514a-3p, miR-509-3p, miR-204-5p, miR-509-5p,
miR-513b, miR-145-5p, miR-146a-5p, miR-508-3p, miR-506-3p, miR-
513c-5p, miR-4731-5p, miR-508-5p, miR-363-3p, miR-4487, miR-
4469, miR-4706, andmiR-16. This panel was carried forward for testing
in independent cohorts of FFPEmelanoma tumours and patient derived
sera.
2.7. Reverse Transcription, Pre-ampliﬁcation, Taqman Assays and Fluidigm
Real-time PCR
We performed a custom Taqman assay combined with a sensitive
method of detection (Fluidigm, HD Biomark) as previously described
(Tembe et al., 2015). Brieﬂy, a custom reverse transcription (RT) primer
pool consisting of equal amounts ofmiRNA-speciﬁc RTprimers contained
within each TaqMan®Assay (Life Technologies, Carlsbad, USA;miR-211-
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675M.S. Stark et al. / EBioMedicine 2 (2015) 671–6805p (000514), miR-514a-3p (001147), miR-509-3p (002236), miR-204-
5p (000508), miR-509-5p (002235), miR-513b (002757), miR-145-5p
(002278), miR-146a-5p (000468), miR-508-3p (001052), miR-506-3p
(001050), miR-513c-5p (002756), miR-4731-5p (464084_mat), miR-
508-5p (002092), miR-363-3p (001271), miR-4487 (462492_mat),
miR-4469 (465059_mat), miR-4706 (464518_mat), and miR-161
(000391) along with cel-miR-39 (000200; serum spiked-in control) and
RNU-6 (001973; FFPE endogenous control)) plus an additional pool of
the corresponding TaqMan® MicroRNA Assay (Pre-Amp Primer Pool)
were used to pre-amplify the RT reaction. Each assay had a serial dilution
of a positive control sample (known expression for all miRNAs in panel)
that had a total input of 1, 3, 15, and 45 ng in the original cDNA reaction.
2.8. qRT-PCR Analysis
The expression of the ‘MELmiR-18’panel (Fig. 1)was assayed in each
sample with at least 4 technical replicate Taqman assays to determine
their expression. Real-time expression data was extracted and analysed
as previously described (Tembe et al., 2015).
2.9. Statistical Methods
Themarker level differences (e.g., univariate analysis of eachmiRNA
in each cohort comparison represented in Table 3) were assessed using
theMann–Whitney U-test and adjusted for multiple comparisons using
the Benjamini & Hochberg method. Signiﬁcantmarkers' predictive abil-
ity was evaluated using receiver operating characteristic (ROC curve)
and area under the curve (AUC) or AUROC. Univariate and multivariate
logistic regressions with backward covariate search based on AIC
(Sakamoto et al., 1986; Vermont et al., 1991)were performed to identify
signiﬁcant markers which were associated with melanoma status/
disease stages, when time to event information was missing. For
survival and recurrence analyses, univariate and multivariate Cox
proportional hazard model with backward covariate search based on
AIC (Sakamoto et al., 1986; Vermont et al., 1991) was performed.
Time to follow-up was measured from date of blood collection which
was ≤1 month of staging. The proportional hazards assumption was
also evaluated for each Cox regression (Grambsch and Therneau,
1994). The model ﬁts were compared using likelihood ratio test. The
predictive abilities of the selected signiﬁcant markers were evaluated
using AUROC. The selected markers were then used to classify patients
using conditional inference tree analysis (Hothorn et al., 2006). For
serum markers, the cutoff point of each marker that characterised the
melanoma status was determined to maximise AUROC statistics.
5000 nonparametric bootstrapswere performed, per cohort (e.g., con-
trols versus stage IV) andmiRNA analysis pairs, to obtain robust effect size
estimates, p values (for univariate analysis) and AUROC. To reﬂect the un-
certainties of the values greater than Ct 36, the values above 36 were re-
placed by random values from 37 to 40 during the bootstrap. The original
data was analysed without this consideration and the ﬁnal models were
rerun using 5000 bootstrap runs to generate robust outcomes.
For the analyses, OptimalCutpoints (v1.1–3), boot, and party
packages onRversion3.0.2were used toﬁnd cutpoints in univariate anal-
yses (cohort vs. markers), bootstrapping and tree analyses respectively.
ROC curves and scatter plots were drawn using GraphPad Prism 6.
Survival analysis was performed using R version 3.0.2.
2.10. Diagnostic Inclusion Criteria, Score Assignment, and Test Evaluation
To maximise the chances of having a positive signal in the patients
serum, a combined stage IV cohort (n = 119; ‘Tubingen’ and ‘MIA’)1 The miR-16 Taqman primer assay (00039) is speciﬁcally designed to bind to mature
miRNA sequence of miR-16-5p which is derived from hsa-miR-16-1 and hsa-miR-16-2
stem–loop sequences. The alias formiR-16-5p ismiR-16 hence the reasoning for the short-
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melanoma or nevi, prior history of melanoma but disease-free, high
nevus count with no melanoma). Initially, all members of the
‘MELmiR-17’ (miR-4469 was excluded due to assay failure) panel
underwent a simple Mann–Whitney U test to identify the highly signif-
icant (p b 0.0001)miRNAs to be included in the next step (Fig. 1). Those
miRNAs that met these criteria then underwent AUROC analysis to
determine their area under the curve (AUC) (Figs. 1 and 2). AUC scores
of ≥0.70 were deemed to be diagnostically useful (Wians, 2009).
The miRNAs that had an AUC of ≥0.70 were interrogated further to
classify themedian-normalised Ct values as ‘high’ or ‘low’ expression (in-
terpretation of themedian normalised Ct expression values used to deter-
mine ROC curves were evaluated with the Optimal Cutoff algorithm
(‘OptimalCutpoints’ R package v1.1–3)). For those miRNAs that met the
criteria for inclusion in the diagnostic panel, the patient was given a diag-
nostic score (ranging from 0 to 7) determined by the number of miRNAs
that were present as ‘high’ and ‘low’ or ‘normal’ (most like the ‘control’
cohort). To be deemed positive for melanoma, the patients sample must
have had a score of ≥4 (max 7). A negative test was a score of 0–3.
The following formulaswere used to determine diagnostic test ability:
Positive Predictive Value (PPV) or Precision = True Positive (TP) /
(TP+ False Positive (FP)); Negative Predictive Value (NPV)= True Neg-
ative (TN) / (False Negative (FN) + TN); Sensitivity = TP / (TP + FN);
Speciﬁcity = TN / (FP + TN) False Positive Rate = 1− Speciﬁcity; False
Negative Rate= 1− Sensitivity; Likelihood Ratio Positive= Sensitivity /
1− Speciﬁcity; Likelihood Ratio Negative=1− Sensitivity / Speciﬁcity;
Diagnostic Odds Ratio (DOR) = (TP / FN) / (FP / TN).
2.11. Funding
This project was funded by the National Health and Medical Re-
search Council (NHMRC) of Australia.
3. Results
3.1. Members of the ‘MELmiR-17’ Panel are Predictors of Stage, Recurrence,
and Survival in Patient Tissue
To conﬁrm that miRNA expression was detectable in melanoma tis-
sues prior to the serum assessment, we ﬁrst measured an 18-miRNA
panel (MELmiR-18) in a prospective collection (Tissue ValidationFig. 2. Expression of MELmiR-7 inCohort, see Materials and Methods) of melanoma tissues derived from
stage III (n = 76) and stage IV (n = 10) melanoma patients (Table 1
and Fig. 1). Expression was detected in all dilutions of a positive control
(except miR-4469 which had assay failure thus the panel herein will be
referred to as ‘MELmiR-17’) and in tissue samples (Fig. 1), which indi-
cated that even at low input levels, the assay and detection method
was adequate (data not shown). We observed that thirteen miRNAs
were differentially expressed when stage III tissues were compared
with stage IV tissues (logistic regression, p b 0.05; Supplementary
Table 1 and Supplementary Fig. 1). All but one of these miRNAs (miR-
204) showed higher levels in stage III compared with stage IV tissues
(Supplementary Table 1 and Supplementary Fig. 1). Of these miRNAs,
seven (miR-506-3p, miR-508-3p, miR-508-5p, miR-509-3p, miR-509-
5p,miR-513c, andmiR-514a)weremembers of themiR-506–514a clus-
ter (Streicher et al., 2012). Supplementary Table 1 summarises the as-
sociated AUROC analyses. Members of the miR-506–514 cluster, had
AUC scores ranging from 0.65 to 0.79 with the highest scores being
shared by miR-506-3p and miR-509-5p. To determine the minimum
number of miRNAs required to discriminate stage III from stage IV,
we next performed a multivariate logistic regression and illustrated
this using a conditional inference tree (Supplementary Fig. 2).
These analyses revealed that only miR-4731 (p = 0.003, OR = 3.0,
CI 1.45–6.2) and miR-204 (p = 0.015, OR = 0.63, CI 0.43–0.92)
were required to discriminate the tissue stage (in general, higher
Ct values = lower expression). Subsequent AUROC analysis
(AUC = 0.89) showed an improved score than individual miRNAs
(Supplementary Table 1).
We next used multivariate Cox regression modelling using the
‘MELmiR-17’ panel together with available records of pathology of the
primary melanoma (SMM, NM) and number of involved nodes (N
stage) to determine its value as a prognostic marker at stage III in the
PAH tissue cohort (Table 1). These analyses showed that only nodular
histotype (NM; p = 0.002; HR = 3.5; CI 1.57–7.81) and expression of
miR-509-5p (p = 0.015; HR = 0.85; CI 0.75–0.97) were associated
with overall survival. Expression levels of the ‘MELmiR-17’ panel were
not signiﬁcantly different between the two largest pathology classes
(SMM and NM) (data not shown). Furthermore, using the same multi-
variate analysis, N-stage (p = 0.014; HR = 1.52; CI 1.09–2.12) and
lower expression of miR-513b (p = 0.038; HR = 1.08; CI 1.00–1.17)
and higher miR-513c expression (p = 0.020; HR = 0.92; CI 0.86–
0.99) were related to recurrence.stage IV progression patients.
Table 4
Sensitivity and speciﬁcity summary.
MELmiR-7-panel Melanoma
vs.
controls
Stages I/II
vs.
controls
Stage III
vs.
controls
Stage IV
vs.
controls
Sensitivity 93% 93% 86% 95%
Speciﬁcity ≥82% ≥82% ≥82% ≥82%
False Positive Rate 18% 18% 18% 18%
False Negative Rate 7% 7% 14% 5%
Positive Predictive Value (PPV) 91% 77% 64% 82%
Negative Predictive Value (PPV) 85% 95% 94% 95%
Likelihood Ratio Positive 5.01 5.04 4.66 5.14
Likelihood Ratio Negative 0.09 0.09 0.17 0.06
Diagnostic Odds Ratio (DOR) 54.86 58.89 27.13 83.18
Table 5
Multivariate survival analysis of serummiRNAs and melanoma stage.
Covariate HR Lower 95% CI Upper 95% CI p value
Stage III 6.03 2.33 15.56 0.0002
Stage IV 8.48 3.12 23.01 b0.0001
hsa-miR-16 1.04 0.88 1.23 ns
hsa-miR-211 0.87 0.82 0.91 b0.0001
hsa-miR-4487 0.88 0.79 0.98 0.02
hsa-miR-4706 0.45 0.29 0.69 0.0002
hsa-miR-4731 0.98 0.90 1.06 ns
hsa-miR-509-3p 1.04 1.00 1.09 ns
hsa-miR-514a 0.92 0.85 0.99 0.02
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Speciﬁcity Using Patient Sera
The ‘MELmiR-17’ panel was next assessed in independent cohorts of
patient sera (serum validation cohorts, see Materials and Methods)
with different stages of disease at time of blood collection (fromnomel-
anoma to stages I–IV) (Table 2 and Fig. 1). All expression values (Ct)
were normalised to cel-miR-39 (synthetic ‘spike-in’ control) according
to previously publishedmethods (Tembe et al., 2015) prior to statistical
analysis. In miRNA derived from serum, expression of 13 miRNAs was
detected (Fig. 1 and Table 3). Notably, the expression of the miR-506–
514a cluster was generally quite low (miR-506-3p and miR-514a) or
not detected (miR-508-3p, miR-508-5p, miR-513b, and miR-513c
(data not shown)). In the 13 detected miRNAs, seven (miR-16, miR-
211-5p, miR-4487, miR-4706, miR-4731, miR-509-3p, and miR-509-
5p) showed highly signiﬁcant differences (Mann–Whitney; corrected
p b 0.0001) between ‘controls’ (no melanoma) and patients with stage
IV disease (Table 3 and Supplementary Figs. 3 and 4). The samemiRNAs
were also differentially detectable in stages I/II and stage III, compared
with ‘controls’, with the exception of miR-211 (Table 3 and Supplemen-
tary Figs. 3 and 4). Whilst miR-16 was originally included as a blood
control, our data show that it is signiﬁcantly associated with disease in
both tissue and serum, as observed previously in a study of colorectal
cancer (Ristau et al., 2014). Intriguingly, levels of expression of most
of these differentially expressed miRNAs were lower in melanoma pa-
tients compared to patients without disease (controls). The miRNAs
−4487,−4706,−4731, 509-3p, and 509-5p all showed lower expres-
sion (on average) and miRNAs −16 and −211 (stage IV only) had
higher expression (on average) in melanoma patients (Supplementary
Fig. 3). The observed lower serum expression of miR-4487, miR-4706,
miR-4731,miR-509-3p, andmiR-509-5p in themelanoma caseswas as-
sociated with melanoma (presence of or recently removed tumour; see
Discussion), and in the case of miR-509-3p, has been noted previously
by Leidinger et al. (2010).
AUROC analysis revealed which of the differentially detected
miRNAs (Table 3 and Supplementary Fig. 5) have the potential to be
used for diagnostic purposes. Particular attention is paid to those
miRNAs that were able to discriminate stage IV disease (i.e., distal
metastatic deposits) from disease-free controls (Table 3). These were:
miR-16, miR-211-5p, miR-4487, miR-4706, miR-4731, miR-509-3p,
and miR-509-5p (herein referred to as ‘MELmiR-7’). Multivariate
logistic regression identiﬁed the ﬁve most robust markers of the
‘MELmiR-7’ panel (miR-211, p b 0.0001; miR-509-3p, p = 0.0014;
miR-509-5p, p b 0.0001; miR-4706, p = 0.028; and miR-4731,
p b 0.0001). Subsequent AUROC analysis revealed these ﬁve markers
produced a near perfect AUC score of 0.9907 (cf. ‘MELmiR-7’ =
0.9911). Furthermore, a conditional inference tree analysis highlighted
that patients could be discriminated into categories based on combina-
tions of expression levels by members of the MELmiR-7 panel. Supple-
mentary Fig. 6 illustrates that only four miRNAs (miR-509-5p, miR-
miR-4731, miR-211, and miR-509-3p) were required to discriminate
the stage IV samples (AUC = 0.9738) from controls. Further compari-
sons showed that ‘MELmiR-7’ panel members can also discriminate
stages I/II (AUC = 0.991) and stage III (AUC = 0.9722) from ‘controls’
(Supplementary Figs. 7 and 8).
The sensitivity and speciﬁcity of the ‘MELmiR-7’ was then assessed
by assigning a diagnostic score to the data. The expression values
graphed in the Supplementary Fig. 3 were used to observe the direction
of the data (i.e., higher or lower expression in ‘controls’ vs. all stages).
The optimal cut points (Vermont et al., 1991) in the AUROC datasets
were identiﬁed which allowed the expression values to be categorised
as positive or negative for melanoma (see Materials and Methods). A
diagnostic score (see Materials and Methods) was then applied to
each sample which ranged from 0 to 3 (low likelihood of melanoma)
and 4 to 7 (high likelihood of melanoma). Upon applying the derived
diagnostic score, the ‘MELmiR-7’ panel was evaluated as a group. Wefound that it had the ability to identify melanoma (independent of
stage), when ≥4 miRNAs (93% sensitivity and ≥82% speciﬁcity) reached
or exceeded their optimal cut point (Table 4). The sensitivity of the
‘MELmiR-7’ panel increased to 95% in the stage IV cohort. Table 4 pro-
vides a summary of the effectiveness of the ‘MELmiR-7’ panel in relation
to other stages. The diagnostic odds ratio (DOR) was used to determine
the lowest diagnostic score possible for the ‘MELmiR-7’ panelwhilst still
maintaining very high sensitivity and speciﬁcity. Moreover, upon com-
parison with currently used serological tests (LDH and S100B), we
found that the ‘MELmiR-7’ panel wasmore sensitive than the combined
power of both tests. Using the available data (Tubingen cohort), elevat-
ed levels of LDH and S100Bwere found in 40% (27/67) and 63% (42/67)
of these patients (Table 2). In the same patients, the ‘MELmiR-7’ panel
achieved 91% (63/67) (when ≥4 miRNAs reached or exceeded their op-
timal cut-points) sensitivity and ≥82% speciﬁcity (speciﬁcity could not
be determined for serum LDH and S100B as ‘controls’ were not
assayed). The sensitivity of the ‘MELmiR-7’ panel was conﬁrmed in an
independent serial collection of stage IV patients (initial blood draw at
lower disease burden and one at a higher disease burden) (Fig. 2).
Fig. 2 highlights that the ‘MELmiR-7’ panel can be used to monitor tu-
mour progression in 100% of the patients assessed (≥2 miRNAs with
≥1.5-fold relative expression). Subsequent AUROC analysis (Fig. 2)
highlights that if measured in isolation, the most informative markers
would be miR-509-5p and miR-4731 (AUC= 0.84) respectively.
3.3. Members of the ‘MELmiR-17’ Differentiate Stage and are Associated
With Survival in Patient Sera
To discern whether signiﬁcant differences in stage could be
found, we ﬁrst assessed the ‘MELmiR-17’ panel using Mann–Whit-
ney tests (with corrected p values) combined with AUROC analysis
for stages I/II vs. IV and stages III vs. IV. Table 3 summarises the asso-
ciated corrected p values and AUROC scores. Next, multivariate logis-
tic regression was used to identify the minimummiRNAs required to
predict differences in the melanoma stages which was illustrated
using conditional inference trees (Supplementary Figs. 9 and 10)
and AUROC analysis (AUC scores for stages I/II vs. IV and stages III
vs. IV were 0.989 and 0.9945 respectively). There were no markers,
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when Cox regression was performed.
The ‘MELmiR-17’panelwas next assessed to identifymiRNAs related
to OS in the serum cohorts from Tubingen (n = 131) and Melanoma
Institute of Australia (MIA; n = 124) ﬁrst separately and then jointly
(n = 255) (Table 2). The predictive performance of the joint model on
each cohort was statistically equivalent to that of the best separate
analysis on each cohort (likelihood ratio test; p = 0.34 for MIA co-
hort; p = 0.22 for Tubingen cohort), hence the joint model was
used to analyse the combined Tubingen and MIA cohorts. Further-
more, the miR-4706 marker was dichotomised at Ct 37 to meet the
proportionality assumption. The outcome from the combined
analysis is summarised in Table 5.
A conditional inference tree analysis for the survival data was then
performed which showed that stage at blood draw together with miR-
211 expression could be used to triage patients based on overall survival
(OS) status (Fig. 3 with Kaplan–Meier plots per each classiﬁcation).
Importantly, upon diagnosis with stage IV, miR-211 expression was
able to discern survival based on high (Ct ≤ 24; median survival =
4.8 months, CI 4.5–5.9) and low expression (Ct ≥ 24.01; median
survival = 2.7 years, CI 1.7–NA).
Finally, the MELmiR-7 panel was further assessed for its utility in
terms of predicting OS in serum cohorts having LDH and S100B status
available (Tubingen) (Table 2). The ‘MELmiR-7’ panel performed signif-
icantly better than both serum LDH and S100B (delta log likelihood =
11, p b 0.001).
4. Discussion
Five-year survival proportions for melanoma are poor for patients
with metastatic disease, however if disease is detected in its early
stages, then survival is one of the highest for all cancers. Even for
those with metastases, survival differs depending on the extent ofFig. 3. Conditional inference tree pdisease spread. Patients with metastases conﬁned to regional lymph
nodes (stage III disease) have 5-year survival of ~50%, whereas patients
with widely disseminated metastases (stage IV disease) have 5-year
survival of b15%. Thus better monitoring of a patient's tumour burden
may improve survival by precipitating earlier therapeutic interventions.
In support of this, clinical trials in stage III unresectable and stage IV
melanoma patients, treated with ipilimumab (Hodi et al., 2010),
vemurafenib (Sosman et al., 2012), combined dabrafenib and
trametinib (Flaherty et al., 2014) or anti-PD1 pembrolizumab (Joseph
et al., 2014), have observed improved overall survival and response
rate in patients with lower disease volume (M1a/M1b) as compared
to those with distal disease (M1c). Moreover, it is believed that there
is potential for long-term survival if relapses are identiﬁed promptly
with treatment initiated without delay (Davidson et al., 2014). In clini-
cal practice, there is currently a lack of reliable, sensitive and speciﬁc
predictive biomarkers for detecting early melanoma progression. This
study aimed to identify a more effective biomarker that was sensitive
and speciﬁc enough to identify early metastatic disease. Since com-
mencement of this study there have been a number of studies investi-
gating the utility of miRNAs to serve as melanoma blood and tissue
biomarkers (Fleming et al., 2015; Friedman et al., 2012; Tembe et al.,
2015; Leidinger et al., 2010; Greenberg et al., 2013; Margue et al.,
2015; Bonazzi et al., 2012). For example, a study by Friedman et al.
(2012) screened 355 miRNAs in sera from 80 melanoma patients
using a previously characterised panel of serum-expressed miRNAs.
The authors found detectable expression for 170 miRNAs and a panel
of ﬁve miRNAs (miR-150, miR-15b, miR-199a-5p, miR-33a, and miR-
424) showed a signiﬁcant association with recurrence-free survival.
This ﬁve-miRNA signature was able to classify the patients into high
and low recurrence risk. Our approach was to identify a panel of
melanoma-related miRNAs that involved ﬁrst screening a panel of
melanoma cell lines (n = 55) in comparison with a group of other
solid malignancies (cell lines were derived from breast, ovarian,redicting survival outcomes.
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miRNA panel indentiﬁed by Friedman et al. (2012) was not present in
our dataset which may indicate that this panel is not speciﬁcally
melanoma-related but instead related to the tumourigenic process.
We focused on miRNAs that were highly expressed or more predomi-
nantly expressed in melanoma with the premise that these may be
both ‘diagnostic’ for melanoma and/or more easily detectable in patient
serum. Our current approach differed from the aforementioned studies
as: 1) this study harnessed the power of our previous comprehensive
analysis of known miRNAs (n = 1898) in relation to melanoma (Stark
et al., 2015); 2) this study validated the cell-line derived miRNA panel
(MELmiR-17) in a large of panel of stage III and IV melanoma tissues
prior to serum analysis to conﬁrm they were expressed; and 3) this
study used an ultra-sensitive method of detection (see Materials and
Methods) to ensure that lowly expressed miRNAs could be detected.
We have successfully used these approaches in a previous study
where a panel of miRNAs were identiﬁed that was related to good and
poor prognosis in stage III melanoma patients (Tembe et al., 2015).
However, our current study was limited by the lack of available serially
collected specimens (to detect recurrence as in Friedman et al., 2012) at
time of study design. To address this limitation, further studies in larger,
independent, prospectively collected melanoma cohorts will be
required to strengthen these data.
In sum, we found that a ‘melanoma-related’ panel of miRNAs was
expressed in metastatic melanoma in a stage-speciﬁc manner and, to-
getherwith the tissue pathology andnodal status,wasprognostic for re-
currence and OS. These markers may therefore also be useful to support
histopathologic diagnosis ofmetastatic deposits suspected of beingmel-
anoma. We further observed that expression of the various miRNAs
from the MELmiR-17 panel in stage IV tissues was often lower than in
stage III tissue, which is in keeping with previous studies. For example,
miR-211 expression is commonly lost in subsets of melanoma cell
lines (Stark et al., 2015; Boyle et al., 2011), and miR-506, a member of
the miR-506–514 cluster, has been shown to be lost during metastatic
colonisation despite being up-regulated in early melanoma progression
(Streicher et al., 2012; Mueller et al., 2009). We have also recently re-
ported that inhibition of miR-514a leads to increased cell proliferation
(Stark et al., 2015). These data indicate that expression of this cluster
reduces during melanoma progression.
Currently there is an unmet need for aminimally invasive, highly spe-
ciﬁc, and predictive serum biomarker of melanoma burden. For many
years the use of the seroproteinmarkers S100B and LDH has been disput-
ed, due to reported inconsistencies in sensitivity and speciﬁcity (Brochez
and Naeyaert, 2000; Finck et al., 1983; Karakousis et al., 1996; Sirott et al.,
1993; Weide et al., 2012; Guo et al., 1995; Smit et al., 2005; Kruijff et al.,
2009). Despite this lack of consensus, a recent study didﬁnd that elevated
levels of S100B were prognostic of survival times in patients with
unresectable melanoma (Weide et al., 2013).
Here, we present data that shows that our ‘MELmiR-7’ panel has the
potential to be used as a primary screening tool for clinically undetected
metastatic melanoma due to its high sensitivity (93%) and speciﬁcity
(≥82%). However, detection of early melanoma lesions (in situ and stages
I/IImelanoma) is currently being adequately achieved (as evident by high
survival rates) via clinical strategies. The ‘MELmiR-7’ panel could be
utilised during routine follow-up (i.e., post-primary excision ofmelanoma
and later in advanced disease) of melanoma patients. In comparisonwith
serum LDH and S100B, expression levels of the ‘MELmiR-7’ panel per-
formed better than both markers in predicting overall survival. We have
shown that the ‘MELmiR-7’ panel was measurable at time of progression
in 100% of stage IVmelanoma patients. These data suggest that this panel
would therefore be suited to monitor tumour burden.
According to the AJCC Staging committee, stage III melanoma
patients have a 50% chance of survival beyond 5 years (Balch et al.,
2009); these patients also remain themost difﬁcult forwhom to provide
effective treatments/surveillance regimens and accurate survival esti-
mates. Following treatment, stage III patients are subjected to a seriesof physical examinations, scans and serology at regular intervals. The fre-
quency of these tests is deemed necessary for early detection of
recurrence; however this causes a burden to both the patient and the
healthcare system. It is important to note that these guidelines are not uni-
versally accepted and differ from centre to centre (Leiter et al., 2014). We
foresee that the ‘MELmiR-7’ panel could be offered to patients to comple-
ment physical examination. If the diagnostic score for melanoma positivity
has changed from earlier measurements, then this may indicate the pres-
ence of disease recurrence and as such, these patients may qualify earlier
for adjuvant, systemic, or targeted therapies that would otherwise be only
offered to stage IV patients. As previously discussed, due to the panel's
high sensitivity and speciﬁcity, the use of this miRNA panel in this manner
has the potential to increase the chances of survival, by earlier and more
precise detection of the presence of metastases.
In terms of prognosis, elevatedmiR-211 expression levelswere asso-
ciated with poorer survival in stage IV patients. Therefore, miR-211
measurement might allow better triaging of patients diagnosed with
stage IV disease, into good and poor prognosis which would be highly
informative for not only the treating clinician but also for the quality
of life of the patients.
The original premise of this study was that the melanoma-enriched
miRNAs identiﬁed in our previous study (Stark et al., 2015) would be
translated directly to the expression observed in melanoma patient-
derived serum. Evidence for this notion is apparent in the serially collect-
ed stage IVmelanomapatients,when, at progression (or recurrence), the
MELmiR-7 panel increases, which is reﬂective of increased tumour
burden (i.e., the detectable miRNA expression was from the presence
of tumour cells and/or tumour derived extracellular vesicles (e.g.,
exosomes) in the circulation). These data strongly suggest that the
expression is tumour derived and as such this panel could be considered
melanoma-related. However, aswehave noted,we observe a paradoxical
decrease in the expression of the signiﬁcantly expressed (miR-509-5p,
miR-509-3p, miR-4731-5p, miR-4487, miR-4706) miRNAs when mela-
noma serum cohorts were compared with control cohorts. These data
thus provide evidence that the assessed miRNAs (detectable in serum)
are not restricted to the melanocytic lineage as initially thought. The
source of this miRNA expression is currently unknown but could include
cells of the haematopoietic lineage including T-cells, B-cells and NK cells.
This loss of expression from a ‘non-tumour’ source has not been eluci-
dated butwarrants further investigation. An observed loss of expression
of serum-derived miRNAs has been noted previously by Friedman et al.
(2012) in post-operative specimens as compared to specimens collect-
ed at disease relapse. A plausible reason for a loss of expression observed
in the serummay be due to a cytokine-driven systemic response. For ex-
ample, pro-inﬂammatory cytokines have been shown to down-regulate
miRNAs present in the circulation (Noren Hooten et al., 2013). Speciﬁcal-
ly, in a study by Noren Hooten et al. (2013) the serum expression of miR-
181a was found to be negatively correlated with pro-inﬂammatory cyto-
kines IL-6 and TNFα and positively correlatedwith the anti-inﬂammatory
cytokines TGFβ and IL-10 (Noren Hooten et al., 2013). Recently, it has
been conﬁrmed that IL-6 expression is induced in melanoma cells with
mutant BRAF (V600E). Therefore a possible explanation for what we
have observed is that the miRNAs of interest could be expressed by
non-melanocyte derived cells where expression is down-regulated in pa-
tients with melanoma due to melanoma-related cytokines (e.g. IL-6)
(Whipple and Brinckerhoff, 2014).
In conclusion, we envisage that as a growing number of miRNA-
panels have been identiﬁed as potential prognostic indicators for mela-
noma (Fleming et al., 2015; Friedman et al., 2012; Tembe et al., 2015), it
will eminently feasible to quantify circulating cell-free miRNAs directly
(Ono et al., 2015), paving the way for rapid measurements to occur in a
diagnostic laboratory. Given these advances, combined with the data
presented herein, future melanoma treatment regimens should consid-
er the utility of miRNAs as a prognostic aid in the clinical setting.
Our sensitive and speciﬁc miRNA panel, in combination with newly
identiﬁed panels, may enable more precise measurement of disease
680 M.S. Stark et al. / EBioMedicine 2 (2015) 671–680progression, and in conjunction with current therapy options, may
herald an increase in overall survival.
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